Article info
PDFOriginal research
Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials
- Correspondence to Professor Mona Abdel-Tawab, Central Laboratory of German Pharmacists, Eschborn 65760, Germany; m.tawab{at}zentrallabor.com
Citation
Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials
Publication history
- Received February 11, 2022
- Accepted June 21, 2022
- First published July 19, 2022.
Online issue publication
February 28, 2024
Article Versions
- Previous version (19 July 2022).
- Previous version (26 July 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2024. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.